Loading quotes...

Forecast

Buy	6
Hold	4
Sell	2

News Go to news feed

Genmab achieves positive study data on petosemtamab and reaches new all-time high

Genmab presented data on petosemtamab that show clinical success in head‑and‑neck tumors and underscore the quality of its own research. Stable revenues from the multiple myeloma drug Darzalex enable the company to expand independent oncology commercialization. The progress contributed to a fresh all‑time high for the stock. » More on finanzen.net
Genmab achieves positive phase‑3 data for petosemtamab and stock rises 25 percent

The phase‑3 LiGeR‑HN1 study shows that petosemtamab in combination with pembrolizumab met both primary endpoints in PD‑L1‑positive head and neck squamous cell carcinoma and reduced the risk of death by 50 percent. Genmab now plans to begin talks with global regulators and to present detailed results at a scientific conference. The news propelled the stock up about 25 percent and for now eases concerns about revenue risks following the Darzalex patent expiry. » More on deraktionaer.de
Genmab: positive Phase‑2 data on petosemtamab in metastatic colorectal cancer

Petosemtamab showed response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer in Phase‑2 combination studies with standard chemotherapies. The safety profile was solid, with treatment-related discontinuation rates of 3–5% and no treatment-related deaths. The mature data support the global Phase‑3 program and underscore the commercial potential of the bispecific agent. » More on finanzen.net

Financials

In the last quarter, Genmab had revenue of €1.01B and net profit of €265.49M

(EUR)	June 2026	YoY
Revenue	1.01B	28.98%
Gross profit	938.42M	27.46%
Net profit	265.49M	6.85%
EBITDA	377.65M	0.62%

Fundamentals

Metric	Value
Market capitalization	€31.82B
Number of shares	61.49M
52-week high/low	€525.17 - €202.31
Dividends	No
Beta	0.65
P/E ratio	45.04
PEG ratio	-0.53
P/B ratio	5.94
P/S ratio	3.68

Company profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.